Reverse merger and financing to fund Oruka pipeline

Oruka Therapeutics, a US biotech focused on developing biologics designed to set a new standard for the treatment of chronic skin diseases, including plaque psoriasis, has entered into a merger agreement with ARCA biopharma.

The resulting entity will focus on advancing Oruka’s pipeline of biologics, including ORKA-001, an interleukin (IL)-23p19 inhibitor, and ORKA-002, an IL-17A/F inhibitor.

Upon completion of the merger, the combined company plans to operate under the name Oruka Therapeutics, and trade on Nasdaq under the ticker symbol ‘ORKA’.